Olanzapine Reduces Nausea Caused by Advanced Cancer; FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer - Cancer Currents Blog

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.     Olanzapine Reduces Nausea and Vomiting Caused by Advanced Cancer 06/12/2020 Many advanced cancer patients suffer from chronic nausea and vomiting and there aren't many good treatments available. But a small study suggests that the drug olanzapine (Zyprexa) may fill that gap. With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era 06/11/2020 FDA has approved olaparib (Lynparza) and rucaparib (Rubraca) to treat some men with metastatic prostate cancer. The PARP inhibitors are approved for men whose cancers have stopped responding to hormone treatment and have specific genetic alterations.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892